

NHS England Specialised Services

Clinical panel report

Date: 19 February 2025

Intervention: Stereotactic ablative body radiotherapy

Indication: localised prostate cancer (adults)

URN: 2106

Gateway: 2, Round 2

Programme: Cancer

CRG: Radiotherapy

Information provided to the Panel

Policy Proposition

Title Change Report

Three Paper Evidence Summary completed by Solutions for Public Health

Clinical Priorities Advisory Group (CPAG) Summary Report

Evidence to Decision (EtD) Summary

Equalities and Health Inequalities (EHIA) Assessment

Patient Impact Assessment (PIA)

Blueteq® Form

Policy Working Group (PWG) Appendix

This Policy Proposition recommends the use of stereotactic ablative body radiotherapy (SABR) for the treatment of localised prostate cancer (adults).

The proposition was previously considered at a Clinical Panel meeting in December 2024. A few amendments to the policy document were requested. The Policy Working Group have considered the Panel members comments and have revised the proposition accordingly.

An overview of the proposition and supporting evidence was given briefly to Panel members and the amendments presented. Panel members considered that the requested amendments had been appropriately addressed in the revised documentation.

Recommendation

Clinical Panel recommends that this proposition progresses as a routine commissioning proposition.

Why the panel made these recommendations

Panel members agreed that the proposition had been satisfactorily revised to address previous comments.

Documentation amendments required

None.

Declarations of Interest of Panel Members: None received.

Panel Chair: Anthony Kessel, Deputy Medical Director, Specialised Services

CONFIDENTIAL